Abstract
In a surprise move, Arrowhead Pharmaceuticals is discontinuing development of multiple RNAi drug candidates that use the same delivery technology. The decision comes just weeks after FDA placed a hold on a clinical trial of ARC-520, a hepatitis B treatment, following the death of several non-human primates in a preclinical toxicology study of the drug. Arrowhead is abandoning three programs—ARC-520, ARC-521, and ARC-AAT—that use the same liver-targeted, intravenously administered delivery vehicle. Arrowhead will refocus its R&D on subcutaneous and non-hepatic delivery systems. As a consequence of the changes, the biotech is laying off 30% of its workforce.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
